Discussion about this post

User's avatar
Heather's avatar

From what I can see, squinting at the table, there is a 2 point improvement on the depression scale at 1 week - are you really so sure that is clinically meaningful? I'd appreciate some guidance on accepted norms around the MDRS scale and clinical meaningfulness. I also note that it only increased to 5 point improvement by the end of the study - again, where does that sit? What point difference can you make on that scale with an improvement in somatic symptoms etc but no mood improvement?

I also note that it seems like most patients still were depressed at the end of the Auvelity study - and this is your yee-dee-dah celebration success?!!

Plus the buproprion only group which seems to be the comparison group had a response rate of only 15%, which is really low - I'm used to response rates for depression treatment more like 40%, so I'm wondering what's going on here??? Make the comparison group look really bad so that you look good in relief? It just raises questions... If the comparison group had the typical inert placebo response rate of 40%, the 45% response rate from Auvelity wouldn't look like much and it's certainly lower than the 60% response rate we were told was the standard ballpark response for ADs

These are genuine questions, I'm not just being a pain-in-the-arse medical student ;)

Expand full comment
Ben Egbers's avatar

Cut my life into pieces…

Expand full comment
6 more comments...

No posts